Skip to main content

Cardiovascular disorders

Browse the latest news, expert commentary, and educational content on cardiovascular disorders.


20-09-2021 | Heart failure | News

Gestational diabetes may flag early HF risk

The presence of gestational diabetes mellitus may identify women at an increased risk for experiencing hospitalization for heart failure within the next few years, research suggests.

27-08-2021 | ESC 2021 | Conference coverage | News

EMPEROR-Preserved: A win for empagliflozin in HFpEF

Empagliflozin has become the first medication to demonstrate a clear protective effect in people with heart failure and preserved ejection fraction, report the EMPEROR-Preserved investigators.

06-08-2021 | Heart failure | News

Support for long-term use of dapagliflozin in people with heart failure

Extrapolation of results from the DAPA-HF trial suggests that lifetime use of dapagliflozin will provide continuing benefits for people with heart failure and reduced ejection fraction.

SGLT2 inhibitor use in type 2 diabetes management

Learn about prescribing these medications with guidance from the Improving Diabetes Steering Committee.

  • » A prescribing tool to inform prescribing decisions for SGLT2 inhibitors
  • » SGLT2 inhibitors: Key evidence and implications for clinical practice
  • » Translating SGLT2 inhibitor cardiovascular evidence into practice
  • » This content is intended only for UK healthcare providers and was made possible by educational funding provided by Napp Pharmaceuticals Ltd.

More on cardiovascular disorders

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

Image Credits